Screener
Crinetics Pharmaceuticals CRNX Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Leasehold improvements | $10,127 | $10,003 |
| Lab equipment | 10,165 | 9,960 |
| Office equipment | 2,204 | 2,225 |
| Computers and software | 89 | 60 |
| Property and equipment at cost | 22,585 | 22,248 |
| Less accumulated depreciation and amortization | (9,088) | (7,952) |
| Total | $13,497 | $14,296 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's cumulative cost basis?
- Crinetics Pharmaceuticals (CRNX) reported cumulative cost basis of $22.59M in Q1 2026.
Ask your AI about Crinetics Pharmaceuticals's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude